← All trials
NCT06054269
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 4, 2022
- Primary completion
- Jul 25, 2023
- Completion date
- Nov 4, 2023
- First posted
- Sep 26, 2023
- Last posted
- Oct 23, 2023
- Enrollment
- 192
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Centers for Disease Control and Prevention (CDC)Lead sponsor
- Hospital Nacional Arzobispo LoayzaCollaborator
- Hospital Nacional Arzobispo LoayzaOverall official - principal investigator
- Cayetano Heredia UniversityCollaborator
- Cayetano Heredia UniversityOverall official - principal investigator
- United States NavyCollaborator
- United States NavyOverall official - principal investigator
- United States NavyOfficial
- Cayetano Heredia UniversityOfficial
- Hospital Nacional Arzobispo LoayzaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.